Several mutational markers can indicate responsiveness to vascular endothelial growth factor (VEGF)-targeted therapy in patients with metastatic renal cell carcinoma (mRCC), according to investigators from Utah.
At the 2017 International Kidney Symposium, Andrew W. Hahn, MD, a PGY-3 in the Department of Internal Medicine at the University of Utah/Huntsman Cancer Institute (HCI), in Salt Lake City, presented findings on the role of VHL and TP53 mutations, and the FLT1 germline variant in